{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GM-CSF-in-adjuvant", "query": { "intervention": "GM-CSF-in-adjuvant" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 103, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GM-CSF-in-adjuvant&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-22T01:12:33.141Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00488592", "title": "Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome (MDS)", "Acute Myeloid Leukemia (AML)", "Chronic Myeloid Leukemia (CML)" ], "interventions": [ { "name": "WT1:126-134", "type": "BIOLOGICAL" }, { "name": "PR1:169-177 Peptide", "type": "BIOLOGICAL" }, { "name": "GM-CSF (Sargramostim)", "type": "DRUG" }, { "name": "Montanide adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 10, "start_date": "2007-06", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2021-07-12", "last_synced_at": "2026-09-22T01:12:33.141Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00488592" }, { "nct_id": "NCT00415857", "title": "Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Peptide Vaccine (PR1 Peptide)", "type": "BIOLOGICAL" }, { "name": "Peginterferon alfa-2b", "type": "DRUG" }, { "name": "Imatinib", "type": "DRUG" }, { "name": "GM-CSF", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2006-12", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2018-08-21", "last_synced_at": "2026-09-22T01:12:33.141Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00415857" }, { "nct_id": "NCT00433745", "title": "Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome", "Acute Myeloid Leukemia (AML)", "Chronic Myeloid Leukemia (CML)" ], "interventions": [ { "name": "WT1 Peptide Vaccine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 4, "start_date": "2007-02", "completion_date": "2009-11", "has_results": true, "last_update_posted_date": "2014-07-08", "last_synced_at": "2026-09-22T01:12:33.141Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00433745" }, { "nct_id": "NCT05232916", "title": "Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "GLSI-100", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Greenwich LifeSciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 2250, "start_date": "2022-12-16", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-09-22T01:12:33.141Z", "location_count": 51, "location_summary": "Mobile, Alabama • Goodyear, Arizona • Tucson, Arizona + 44 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05232916" }, { "nct_id": "NCT01265433", "title": "Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Pleural Mesothelioma" ], "interventions": [ { "name": "Galinpepimut-S + Montanide + GM-CSF", "type": "BIOLOGICAL" }, { "name": "Montanide + GM-CSF", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sellas Life Sciences Group", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2010-12-21", "completion_date": "2017-07-25", "has_results": true, "last_update_posted_date": "2024-10-09", "last_synced_at": "2026-09-22T01:12:33.141Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01265433" }, { "nct_id": "NCT00262808", "title": "GM-CSF and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Colon Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2004-03", "completion_date": "2006-09", "has_results": false, "last_update_posted_date": "2013-10-16", "last_synced_at": "2026-09-22T01:12:33.141Z", "location_count": 2, "location_summary": "Rochester, New York • Durham, North Carolina", "locations": [ { "city": "Rochester", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00262808" }, { "nct_id": "NCT01094496", "title": "A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The \"N-ABLE\" Study)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "CDX-1307 Vaccine Regimen", "type": "BIOLOGICAL" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2010-04", "completion_date": "2011-07", "has_results": false, "last_update_posted_date": "2020-02-13", "last_synced_at": "2026-09-22T01:12:33.141Z", "location_count": 17, "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 13 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01094496" }, { "nct_id": "NCT03927222", "title": "Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF", "type": "BIOLOGICAL" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Tetanus-Diphtheria Toxoid (Td)", "type": "BIOLOGICAL" }, { "name": "GM-CSF", "type": "BIOLOGICAL" }, { "name": "111-Indium-labeling of Cells for in vivo Trafficking Studies", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Mustafa Khasraw, MBChB, MD, FRCP, FRACP", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2019-09-30", "completion_date": "2023-02-10", "has_results": true, "last_update_posted_date": "2024-04-08", "last_synced_at": "2026-09-22T01:12:33.141Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03927222" }, { "nct_id": "NCT00079157", "title": "Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "incomplete Freund's adjuvant", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "telomerase: 540-548 peptide vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 28, "start_date": "2004-02", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2020-02-05", "last_synced_at": "2026-09-22T01:12:33.141Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00079157" }, { "nct_id": "NCT00091039", "title": "Vaccine Therapy, Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed With Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "recombinant fowlpox GM-CSF vaccine adjuvant", "type": "BIOLOGICAL" }, { "name": "recombinant fowlpox-CEA(6D)/TRICOM vaccine", "type": "BIOLOGICAL" }, { "name": "recombinant vaccinia-CEA(6D)-TRICOM vaccine", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2004-08", "completion_date": "2006-02", "has_results": false, "last_update_posted_date": "2013-06-20", "last_synced_at": "2026-09-22T01:12:33.141Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00091039" } ] }